Premium
111 Indium‐labeled monoclonal antibody K1: Biodistribution study in nude mice bearing a human carcinoma xenograft expressing mesothelin
Author(s) -
Hassan Raffit,
Wu Chuanchu,
Brechbiel Martin W.,
Margulies Inger,
Kreitman Robert J.,
Pastan Ira
Publication year - 1999
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/(sici)1097-0215(19990209)80:4<559::aid-ijc13>3.0.co;2-y
Subject(s) - mesothelin , monoclonal antibody , biodistribution , antigen , mesothelium , antibody , pathology , cancer research , microbiology and biotechnology , epidermoid carcinoma , carcinoma , biology , medicine , in vivo , immunology , peritoneum
The monoclonal antibody (MAb) K1 is a murine IgG 1 that recognizes mesothelin, a differentiation antigen present on mesothelium which is highly expressed on cancers derived from mesothelium, including most ovarian cancers and epithelioid mesotheliomas. MAb K1 was conjugated to 2‐( p ‐isothiocyanatobenzyl)‐cyclohexyl‐ diethylenetriaminepentaacetic acid and labeled with 111 In. The biodistribution of 111 In‐K1 was studied in athymic nude mice bearing 2 s.c. tumors, one expressing a stably transfected plasmid encoding mesothelin and one composed of the parental untransfected A431 epidermoid carcinoma cells which do not express mesothelin. Tumor‐bearing mice were given an i.v. injection of 111 In‐K1 and killed at different time points to determine the uptake of radiolabeled antibody. Significantly higher uptake was seen in antigen‐positive tumors at all time points, with peak values at 72 hr (52.9% vs. 8% of the injected dose/g tissue for antigen‐positive and antigen‐negative tumors, respectively). Uptake in antigen‐positive tumors was higher than the blood level at all time points, and the tumors contained a high level of the radiolabeled MAb even at 7 days (28.6% of the injected dose/g tumor). Int. J. Cancer80:559–563, 1999. Published 1999 Wiley‐Liss, Inc.